Diabétologie - Nutrition - Endocrinologie : Enrichir et mettre à jour à jour sa panoplie pour mieux soigner, le tri 2012 = Diabetology - Nutrition - Endocrinology : 2012 updateLa Revue Prescrire. 2013, Vol 33, Num 351, pp 39-40, issn 0247-7750, 2 p.Article

Gliptines: pemphigoïdes bulleuses : Les faits marquantsLa Revue Prescrire. 2014, Vol 34, Num 373, issn 0247-7750, p. 829Conference Paper

Linagliptine en ajout à l'insuline ^(TRAJENTA°): Repousser les gliptinesLa Revue Prescrire. 2013, Vol 33, Num 361, issn 0247-7750, p. 814Article

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in MiceWAGET, Aurélie; CABOU, Cendrine; SULPICE, Thierry et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3018-3029, issn 0013-7227, 12 p.Article

Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 SecretagogueSANGLE, Ganesh V; LAUFFER, Lina M; GRIECO, Anthony et al.Endocrinology (Philadelphia). 2012, Vol 153, Num 2, pp 564-573, issn 0013-7227, 10 p.Article

Clinical Pharmacokinetics and Pharmacodynamics of VildagliptinHE, Yan-Ling.Clinical pharmacokinetics. 2012, Vol 51, Num 3, pp 147-162, issn 0312-5963, 16 p.Article

linagliptine ^(TRAJENTA°) Non aux gliptines !La Revue Prescrire. 2012, Vol 32, Num 347, pp 654-656, issn 0247-7750, 3 p.Article

Gliptines: troubles graves pancréatiques, cutanésLa Revue Prescrire. 2014, Vol 34, Num 363, issn 0247-7750, p. 22Article

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes MellitusPLOSKER, Greg L.Drugs (Basel). 2014, Vol 74, Num 2, pp 223-242, issn 0012-6667, 20 p.Article

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patientsSATOH-ASAHARA, Noriko; SASAKI, Yousuke; WADA, Hiromichi et al.Metabolism, clinical and experimental. 2013, Vol 62, Num 3, pp 347-351, issn 0026-0495, 5 p.Article

The effects of sitagliptin on gastric emptying in healthy humans ― a randomised, controlled studySTEVENS, J. E; HOROWITZ, M; DEACON, C. F et al.Alimentary pharmacology & therapeutics. 2012, Vol 36, Num 4, pp 379-390, issn 0269-2813, 12 p.Article

Pancréatite et sitagliptineBABAI, Samy; BROCVIELLE, Hélène; LE LOUET, Hervé et al.Médecine (Montrouge). 2009, Vol 5, Num 9, issn 1777-2044, p. 400Article

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetesGAUTIER, J.-F; SAUVANET, J.-P.Annales d'endocrinologie. 2011, Vol 72, Num 4, pp 287-295, issn 0003-4266, 9 p.Article

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese malesHERMAN, Gary A; MISTRY, Goutam C; DAVIES, Michael J et al.British journal of clinical pharmacology. 2011, Vol 71, Num 3, pp 429-436, issn 0306-5251, 8 p.Article

Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 DiabetesBORJA-HART, Nancy L; WHALEN, Karen L.The Annals of pharmacotherapy. 2010, Vol 44, Num 6, pp 1046-1053, issn 1060-0280, 8 p.Article

Absorption, Metabolism, and Excretion of [¹⁴C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in HumansHANDAN HE; TRAN, Phi; HOWARD, Dan et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 536-544, issn 0090-9556, 9 p.Article

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinelics of the sulphonylurea, glyburide, in healthy subjectsMISTRY, Goutam C; BERGMAN, Arthur J; WEI ZHENG et al.British journal of clinical pharmacology. 2008, Vol 66, Num 1, pp 36-42, issn 0306-5251, 7 p.Article

Sitagliptine : allergies graves = Sitagliptin and severes allergiesLa Revue Prescrire. 2008, Vol 28, Num 302, pp 907-907, issn 0247-7750, 1 p.Article

Diabète: trop de gliptines en FranceLa Revue Prescrire. 2014, Vol 34, Num 368, issn 0247-7750, p. 465Article

saxagliptine ^(ONGLYZA°) seule ou associée: Pas moins de complications, peut-être plus d'insuffisances cardiaquesLa Revue Prescrire. 2014, Vol 34, Num 366, issn 0247-7750, p. 256Article

Pharmacokinetic—Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy VolunteersKIM, Bo-Hyung; SUNG EUN KIM; DONGWOO KANG et al.Basic & clinical pharmacology & toxicology (Print). 2013, Vol 113, Num 2, pp 113-125, issn 1742-7835, 13 p.Article

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitisYILMAZ, Yusuf; YONAL, Oya; DEYNELI, Oguzhan et al.Acta gastro-enterologica belgica (English ed.). 2012, Vol 75, Num 2, pp 240-244, issn 1784-3227, 5 p.Article

Non-Alcoholic Fatty Liver Disease Adversely Affects the Glycemic Control Afforded by SitagliptinIWASAK, Tomoyuki; TOMENO, Wataru; YONEDA, Masato et al.Hepato-gastroenterology. 2012, Vol 59, Num 117, pp 1522-1525, issn 0172-6390, 4 p.Article

Sitagliptin Exerts an Antinflammatory ActionMAKDISSI, Antoine; GHANIM, Husam; VORA, Mehul et al.The Journal of clinical endocrinology and metabolism. 2012, Vol 97, Num 9, pp 3333-3341, issn 0021-972X, 9 p.Article

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic miceJELSING, Jacob; VRANG, Niels; VAN WITTELOOSTUIJN, Søren B et al.Journal of endocrinology. 2012, Vol 214, Num 3, pp 381-387, issn 0022-0795, 7 p.Article